Novartis and Roche likely to lead tussle for AMD market into 2020s, says report

11 January 2019

There are 236 drugs in development for the treatment of age-related macular degeneration (AMD), a report notes.

The GlobalData findings show that Swiss pharma giants Novartis (NOVN: VX) and Roche (ROG: SIX) have the highest number of clinical trials going on in AMD, giving them the chance of future revenues beyond their current blockbuster Lucentis (ranibizumab), the first anti-VEGF monoclonal antibody designed specifically for the wet form of AMD.

At present, the AMD market comprises of only five drugs in the USA, European Union and Japan, and four in China. The market is quite niche and scattered, providing opportunities for pharma majors to compete and claim top positions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK